Assembly Biosciences, Inc. (NASDAQ:ASMB) Expected to Post Earnings of -$0.55 Per Share

Brokerages predict that Assembly Biosciences, Inc. (NASDAQ:ASMB) will announce earnings of ($0.55) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Assembly Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.57) and the highest estimate coming in at ($0.53). Assembly Biosciences posted earnings per share of ($0.09) in the same quarter last year, which would indicate a negative year-over-year growth rate of 511.1%. The company is expected to issue its next earnings results on Thursday, November 4th.

According to Zacks, analysts expect that Assembly Biosciences will report full year earnings of ($2.29) per share for the current financial year, with EPS estimates ranging from ($2.39) to ($2.16). For the next financial year, analysts anticipate that the company will report earnings of ($2.19) per share, with EPS estimates ranging from ($3.24) to ($1.48). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Wednesday, August 4th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.66) by $0.11. Assembly Biosciences had a negative net margin of 78.57% and a negative return on equity of 37.80%.

ASMB has been the topic of several analyst reports. Zacks Investment Research lowered shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, September 8th. HC Wainwright initiated coverage on shares of Assembly Biosciences in a research report on Monday, September 13th. They set a “neutral” rating and a $3.50 price target on the stock. Finally, William Blair lowered shares of Assembly Biosciences from an “outperform” rating to a “market perform” rating and set a $3.10 price target on the stock. in a research report on Thursday, September 2nd. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.91.

In related news, CEO John G. Mchutchison sold 12,156 shares of Assembly Biosciences stock in a transaction dated Monday, August 9th. The shares were sold at an average price of $3.60, for a total transaction of $43,761.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.90% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. SG3 Management LLC purchased a new position in Assembly Biosciences in the 2nd quarter worth about $39,000. Royal Bank of Canada increased its stake in Assembly Biosciences by 185.4% in the 2nd quarter. Royal Bank of Canada now owns 10,319 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 6,703 shares in the last quarter. Pinnacle Wealth Planning Services Inc. acquired a new stake in Assembly Biosciences during the 2nd quarter worth about $42,000. New York Life Investments Alternatives acquired a new stake in Assembly Biosciences during the 2nd quarter worth about $44,000. Finally, Bridgefront Capital LLC acquired a new stake in Assembly Biosciences during the 2nd quarter worth about $45,000. 65.08% of the stock is currently owned by hedge funds and other institutional investors.

ASMB stock remained flat at $$3.23 during midday trading on Wednesday. 9,847 shares of the company traded hands, compared to its average volume of 1,135,883. The firm has a market capitalization of $145.26 million, a price-to-earnings ratio of -1.32 and a beta of 0.34. The company’s fifty day moving average is $3.49 and its two-hundred day moving average is $3.97. Assembly Biosciences has a 52 week low of $3.09 and a 52 week high of $17.54.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate.

See Also: Golden Cross

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.